Authors/Disclosures
|
Joseph F. Quinn, MD, FAAN
(OHSU Neurology)
|
Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Retrophin. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Disease Cooperative Study. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Therapeutic Research Institute. Dr. Quinn has a non-compensated relationship as a consultant with Cognition Therapeutics that is relevant to AAN interests or activities. |
|
Meiko Maeda, MD, PhD
(Tokyo university)
|
No disclosure on file |
|
Jeffrey A. Kaye, MD, FAAN
(Oregon Hlth Sci Univ.)
|
Dr. Kaye has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Kaye has stock in Life Analytics. The institution of Dr. Kaye has received research support from NIH. The institution of Dr. Kaye has received research support from NSF. The institution of Dr. Kaye has received research support from AbbVie. Dr. Kaye has received intellectual property interests from a discovery or technology relating to health care. |
|
Hana Vranova, MD
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |